RSV

AZD4316 is an inhibitor of the respiratory syncytial virus (RSV) L protein, demonstrating significant antiviral activity against RSV A subtypes, including strain A2. This compound effectively hinders viral replication during the early stages of infection, particularly at the viral entry phase. However, its efficacy diminishes when administered 12-24 hours post-infection. AZD4316 is valuable for research focused on RSV infection mechanisms and potential therapeutic strategies.

RSV-IN-13 is a selective inhibitor of respiratory syncytial virus (RSV) fusion protein, exhibiting antiviral activity. It demonstrates an EC50 of 444.2 nM against the RSV A2 strain, with a CC90 of 23.7 μM in HepG2 cells. By effectively blocking the entry of the virus into host cells, RSV-IN-13 serves as a valuable tool for research on RSV infection and pathogenesis.

A 33903 is a selective inhibitor of respiratory syncytial virus (RSV) replication. It demonstrates significant antiviral activity against RSV, making it a valuable tool for researchers studying RSV infections and related therapeutic interventions. This reagent can facilitate investigations into viral pathogenesis and the development of antiviral strategies.

4,5-O-Dicaffeoyl quinic acid methyl ester is a potent antiviral agent specifically targeting respiratory syncytial virus (RSV). It exhibits strong inhibitory activity with an IC50 value of 0.63 μg/mL, indicating effective suppression of viral replication. The compound's safety profile is substantiated by a CC50 of 118.68 μg/mL, supporting its potential use in research applications focused on RSV-related therapeutic strategies.

RSV-IN-3 is a dual inhibitor targeting respiratory syncytial virus (RSV) and influenza virus A (IAV). It demonstrates significant anti-RSV activity with an EC50 value of 32.70 μM. RSV-IN-3 can be utilized in research focused on viral pathogenesis and the development of antiviral therapeutics for respiratory viral infections.

RSV/IAV-IN-3 is a dual inhibitor targeting both respiratory syncytial virus (RSV) and influenza A virus (IAV) with reported EC50 values of 2.92 µM and 1.90 µM, respectively. This compound exhibits significant antiviral activity against H1N1 and H3N2 strains, achieving EC50 values of 3.25 µM and 1.50 µM in MDCK cells. Notably, RSV/IAV-IN-3 inhibits IAV infectivity and RNA-dependent RNA polymerase (RdRp) activity while effectively suppressing viral replication at the post-entry stage. Its influence on luciferase activity further emphasizes its potential in antiviral research applications.

RSV-IN-4 is a dual inhibitor targeting respiratory syncytial virus (RSV) and influenza virus A (IAV). This compound demonstrates significant anti-RSV activity, achieving an EC50 of 11.76 μM. RSV-IN-4 is primarily utilized in research applications focused on antiviral drug development and understanding viral pathogenesis.

RSV/IAV-IN-2 is a potent dual inhibitor targeting respiratory syncytial virus (RSV) and influenza A virus (IAV). This compound demonstrates reduced cytotoxicity compared to the established antiviral Ribavirin, making it a valuable candidate for studies focused on RSV and/or IAV infections. Its efficacy in inhibiting viral replication supports its use in antiviral research and therapeutic development against these respiratory pathogens.

RSV/IAV-IN-1 is a potent dual inhibitor targeting respiratory syncytial virus (RSV) and influenza A virus (IAV). This compound exhibits reduced cytotoxicity compared to the clinical antiviral agent Ribavirin, making it a valuable tool for studying RSV and IAV infections. RSV/IAV-IN-1 facilitates research into antiviral mechanisms and therapeutic strategies against these viral pathogens.